Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular methylprednisolone for axial spondyloarthritis with high disease activity
NL-OMON52017Phase 3Not yet recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylprednisolone in axial spondyloarthritis (axSpA), sponsored by Franciscus Gasthuis & Vlietland. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
methylprednisolone
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON52017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52017.